![](https://www.cmgassets.com/s3fs-public/styles/article_node_main_image/public/2024-05/national-cancer-institute-mbl91lg56zc-unsplash.jpg?h=a0def058&itok=J6gp509r)
Companion diagnostics market foresees 15.2% CAGR until 2028
The global market is estimated to reach $15.4b within the forecast period.
The global companion diagnostics market is expected to reach $15.4b by 2028 at a compound annual growth rate (CAGR) of 15.2%, according to BCC Research.
The report revealed that the market was driven by factors such as the rising incidence of cancer, an increasing need for personalised medicine, and advances in next-generation sequencing (NGS) technologies.
ALSO READ: Long-term care market projects 3.33% CAGR until 2027
Moreover, an expanded application of treatments and tools in non-oncology areas has also driven the market’s growth.
Tests or therapies originally specified for cancer may now be applied to conditions including brain diseases, heart problems, infections, and other illnesses.